OKYO Stock Discussion
OKYO Pharma Limited Description
OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) is a biotechnology company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain. OKYO’s research program is focused on a novel G Protein-Coupled Receptor, or GPCR, which OKYO believes plays a key role in the pathology of these inflammatory eye diseases of high unmet medical need. OKYO’s therapeutic approach is focused on targeting inflammatory and pain modulation pathways that drive these conditions. The Company is presently developing OK-101, its lead preclinical product candidate, for the treatment of dry-eye disease “DED”. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis.
Industry: Biotechnology
Keywords: Biotechnology Clinical Medicine Immunology Pain Eye Diseases Inflammatory Uveitis Allergic Conjunctivitis Dry Eye Disease Conjunctivitis Measles Treatment Of Dry Eye Disease
Recent Comments
- LillyMilly1 on LILM
- LillyMilly1 on LILM
- TraderMike on RYDE what a RIDE!!! Holy Crap!
- Crunching_The_Market on RYDE what a RIDE!!! Holy Crap!
- LillyMilly1 on LILM
From the Blog
Popular Now
Featured Articles